Compare Indonesia Energy Corporation Limited (INDO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs State Street SPDR S&P Biotech ETF — how do they compare? Indonesia Energy Corporation Limited trades at $2.77 (market cap $43.24M), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 233.8× Indonesia Energy Corporation Limited's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| INDO | XBI | |
|---|---|---|
Market Cap | $43.24M | $10.11B |
Volume | 116,953 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $6.74 | $169.55 |
52-Week Low | $2.49 | $104.99 |
Typical Hold Time | 24 Days | 38 Days |
Enterprise Value | $38.18M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Indonesia Energy Corporation (INDO) trades at $2.79, up 0.72% with bearish technical signals despite 100% analyst buy ratings. The oil and gas explorer shows severe financial distress with negative margins (-152.72% net income) and cash burn, though recent K-29 well discoveries offer operational catalysts. Revenue remains minimal at $2.01M while losses persist, creating high-risk speculation around drilling success.
Outlook hinges on production scaling from new wells, but current fundamentals don't support valuation. High execution risk and cash flow concerns warrant caution despite optimistic analyst coverage. The stock represents a binary bet on operational turnaround versus ongoing financial deterioration.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
